{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038854","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.904902+00:00","generated_at":"2026-06-04T04:35:17.374378+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akari Therapeutics FY2023 net loss narrows to $10M; all-stock merger with Peak Bio","bullets":["FY2023 net loss $10.0M vs $17.7M in 2022; cash $3.8M at year-end, raised $2.0M in March 2024.","Merger as equals with Peak Bio in all-stock transaction; combined pipeline includes ADC, NEI, nomacopan, PAS-nomacopan.","Nomacopan Phase 3 for pediatric HSCT-TMA ongoing: 10 patients treated; orphan drug and rare pediatric disease designations.","R&D expenses $5.5M (down 43% YoY); G&A $11.4M (down 16% YoY); additional capital planned Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038854","json":"https://secwatch.observer/filing/0000950170-24-038854.json","markdown":"https://secwatch.observer/filing/0000950170-24-038854.md","text":"https://secwatch.observer/filing/0000950170-24-038854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/0000950170-24-038854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/aktx-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:35:17.374378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3f593fa77af9d4eb8c680b00e63966883bb0d97","claim":"Akari Therapeutics Plc reported the full year ended December 31, 2023 results: net income Net loss was approximately $10.0 million for the year ended December 31, 2023.","evidence_excerpt":"Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/0000950170-24-038854-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"Net loss was approximately $10.0 million for the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}